Article Link: FDA Approves Tazverik (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 23, 2020– Epizyme, Inc. (Nasdaq: EPZM), a biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of…

Source: FDA New Drug Approvals